BRENDA - Reference to 3.4.22.26; Id = 697471

antiCP polyclonal antibody

-

Rattus norvegicus

antiFVIIa polyclonal antibody

-

Rattus norvegicus

additional information

Rattus norvegicus

cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII

?

-

additional information

Rattus norvegicus

rat and human cancer procoagulant activity bind similarly to antiCP antibodies

?

-

Rattus norvegicus

-

Lobund-Wistar rat with transplanted PA-3 prostate tumors

-

harvested PA3 tumors are extracted in 0.02 M Tris (pH 7.8), after centrifugation extracts are purified by ion-exchange chromatography, fractions containing CP activity are desalted and concentrated by ultrafiltration on YM10 membrane and redissolved in 2-3 ml of 0.02 M Tris

Rattus norvegicus

prostate gland cancer cell

prostate tumor

Rattus norvegicus

-

additional information

-

enzyme has procoagulant activity

Rattus norvegicus

0.059

-

crude extract from independent PA3 tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.068

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.078

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.082

-

crude extract from independent PA3 rat prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.098

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

2.26

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 33fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

2.32

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 30fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

4.91

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 50fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

7.7

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 133fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

16.6

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 202fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

additional information

cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII

697471

Rattus norvegicus

?

-

additional information

rat and human cancer procoagulant activity bind similarly to antiCP antibodies

697471

Rattus norvegicus

?

-

Sar-Pro-Arg-p-nitroanilide + H2O

-

697471

Rattus norvegicus

Sar-Pro-Arg + p-nitroaniline

-

?

7.8

-

assay at

Rattus norvegicus

additional information

-

cancer procoagulant activity from 4 independent prostate tumors is assayed, inhibition of FX-activating activity of cancer procoagulant-containing extracts by use of a polyclonal antiFVIIa antibody, samples obtained from 1-step purification of crude extract are tested for the presence of tissue factor or FVIIa activity in inhibition assay using antirat factor VIIa polyclonal antibodies, 0% inhibition of cancer procoagulant sample 1, 0.4% inhibition of cancer procoagulant sample 2, 6.6% inhibition of cancer procoagulant sample 3, 4.9% inhibition of cancer procoagulant sample 4

Rattus norvegicus

additional information

-

cancer procoagulant activity from 4 independent prostate tumors is assayed, inhibition of FX-activating activity of cancer procoagulant-containing extracts by use of a polyclonal antiFVIIa antibody, samples obtained from 1-step purification of crude extract are tested for the presence of tissue factor or FVIIa activity in inhibition assay using antirat factor VIIa polyclonal antibodies, 0% inhibition of cancer procoagulant sample 1, 0.4% inhibition of cancer procoagulant sample 2, 6.6% inhibition of cancer procoagulant sample 3, 4.9% inhibition of cancer procoagulant sample 4

Rattus norvegicus

additional information

antiCP polyclonal antibody

-

Rattus norvegicus

antiFVIIa polyclonal antibody

-

Rattus norvegicus

additional information

Rattus norvegicus

cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII

?

-

additional information

Rattus norvegicus

rat and human cancer procoagulant activity bind similarly to antiCP antibodies

?

-

harvested PA3 tumors are extracted in 0.02 M Tris (pH 7.8), after centrifugation extracts are purified by ion-exchange chromatography, fractions containing CP activity are desalted and concentrated by ultrafiltration on YM10 membrane and redissolved in 2-3 ml of 0.02 M Tris

Rattus norvegicus

prostate gland cancer cell

prostate tumor

Rattus norvegicus

-

additional information

-

enzyme has procoagulant activity

Rattus norvegicus

0.059

-

crude extract from independent PA3 tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.068

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.078

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.082

-

crude extract from independent PA3 rat prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

0.098

-

crude extract from independent PA3 prostate tumor, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

2.26

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 33fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

2.32

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 30fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

4.91

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 50fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

7.7

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 133fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

16.6

-

extract from independent PA3 prostate tumor undergoes 1 round of purification on the anion exchanger, 202fold purification, activity of samples is determined by using a 3-stage chromogenic assay

Rattus norvegicus

additional information

cancer procoagulant is a cysteine protease acting as an activator of coagulation factor X, the protein activates factor X in the absence of tissue factor and factor VII

697471

Rattus norvegicus

?

-

additional information

rat and human cancer procoagulant activity bind similarly to antiCP antibodies

697471

Rattus norvegicus

?

-

Sar-Pro-Arg-p-nitroanilide + H2O

-

697471

Rattus norvegicus

Sar-Pro-Arg + p-nitroaniline

-

?

7.8

-

assay at

Rattus norvegicus

733446

Kee

The effect of cancer procoagul ...

Homo sapiens

Biol. Chem.

393

113-121

2012

-

3

-

1

-

1

-

1

-

701292

Musallam

Incidence and prophylaxis of v ...

Homo sapiens

Thromb. Res.

123

679-686

2009

-

1

-

2

-

1

-

1

-

1

-

710603

Kaplinska

Cancer procoagulant (CP) analy ...

Homo sapiens

Thromb. Res.

124

364-367

2009

-

2

-

1

2

-

2

-

2

-

1

-

2

-

1

2

-

2

-

1

-

697471

Kamocka

Rat prostate tumors express ca ...

Rattus norvegicus

Comp. Med.

58

282-286

2008

-

2

-

2

-

3

-

1

-

2

11

-

3

-

1

-

1

-

1

2

-

2

-

1

-

2

11

-

3

-

1

-

679297

Kamocka

Effect of immunisation with ca ...

Homo sapiens

Clin. Exp. Med.

6

119-123

2006

-

1

-

1

-

1

-

4

-

1

-

2

-

1

-

1

-

1

-

1

-

1

-

2

-

1

-

679638

Szajda

Analysis of the relationship b ...

Homo sapiens

Eur. J. Gynaecol. Oncol.

27

495-499

2006

1

-

1

-

2

-

3

-

1

-

1

-

1

-

3

-

1

-

668075

Kazmierczak

Cancer procoagulant in patient ...

Homo sapiens

Blood Coagul. Fibrinolysis

16

543-547

2005

-

1

-

2

-

2

-

4

1

-

2

-

1

-

2

-

4

1

-

2

-

668137

Kamocka

Effect of cancer procoagulant ...

Homo sapiens

Cancer Lett.

222

89-94

2005

-

1

-

2

-

1

-

1

-

3

-

3

-

1

-

1

-

1

-

2

-

1

-

3

-

3

-

1

-

1

-

668476

Jozwik

The activity of cancer procoag ...

Homo sapiens

Eur. J. Gynaecol. Oncol.

26

407-410

2005

-

1

-

2

-

2

-

7

1

-

4

-

1

-

2

-

7

1

-

4

-

667302

Raasi

Properties of proteins in canc ...

Homo sapiens

Arch. Biochem. Biophys.

428

131-135

2004

-

2

-

2

-

1

-

1

-

1

-

1

-

1

-

2

-

2

-

1

-

1

-

1

-

1

-

651435

Mielicki

Biochemistry of cancer procoag ...

Homo sapiens, Oryctolagus cuniculus

Haemostasis

31 Suppl 1

8-10

2001

8

-

24

-

1

2

1

4

-

2

-

2

1

-

6

-

13

1

-

1

-

8

-

24

1

-

1

2

1

4

-

2

1

-

6

-

13

1

-

1

-

653983

Mielicki

Cancer procoagulant activity s ...

Homo sapiens

Thromb. Res.

87

251-256

1997

-

1

-

2

5

-

1

-

1

-

1

-

3

2

-

18

-

5

1

-

1

-

2

-

5

-

1

-

1

-

3

2

-

18

-

5

1

-

30160

Gordon

Cancer procoagulant ...

Homo sapiens, Rattus norvegicus

Methods Enzymol.

244

568-583

1994

2

-

6

26

-

8

2

-

2

-

7

-

2

-

2

-

2

-

6

-

26

-

8

2

-

2

-

7

-

2

-

2

-

30161

Mielicki

Effect of divalent ions on the ...

Homo sapiens

Arch. Biochem. Biophys.

314

165-170

1994

-

3

-

1

4

-

1

-

1

-

1

-

1

-

3

-

1

4

-

1

-

1

-

1

-

30159

Moore

The purification and propertie ...

Mus musculus

Biochem. Biophys. Res. Commun.

184

819-824

1992

-

12

-

1

-

3

-

1

-

6

-

1

4

1

-

12

-

1

-

1

-

6

-

1

4

1

-

30158

Falanga

Inhibition of cancer procoagul ...

Oryctolagus cuniculus

Thromb. Res.

54

389-398

1989

-

2

-

1

-

3

-

2

-

3

-

30157

Falanga

Several murine metastasizing t ...

Mus musculus, Oryctolagus cuniculus

Int. J. Cancer

39

774-777

1987

-

4

-

4

-

8

-

6

-

4

-

8

-

6

-

30156

Falanga

Isolation and characterization ...

Oryctolagus cuniculus

Biochemistry

24

5558-5567

1985

-

2

-

2

1

-

2

-

1

-

3

-

2

1

-

1

-

2

-

2

1

-

1

-

3

-

2

1

-

1

-

Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X

Data extracted from this reference: